CD19 and acute lymphoblastic leukemia: Another CD19 CAR-T product, brexucabtagene autoleucel (KTE-X19), was tested in a multicenter, phase I trial in 24 children and adolescents with R/R B-ALL (ZUMA-4; NCT02625480).